Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study

Efficacy and safety of upadacitinib as monotherapy or combined with elsubrutinib for the treatment of systemic lupus erythematosus: results through 104 weeks in a long-term extension study

Objectives This 1-year long-term extension (LTE) study (NCT04451772) followed the 48-week phase 2 SLEek study (NCT03978520) that evaluated upadacitinib (a Janus kinase inhibitor) alone or combined with elsubrutinib (a Bruton’s tyrosine kinase inhibitor) in adults with moderately to severely active s...

Full description

Saved in:
Bibliographic Details
Main Authors: Joan T Merrill, Yoshiya Tanaka, Amit Saxena, Xiaofeng Zeng, Martin Aringer, David D’Cruz, Kristin M D’Silva, Ling Cheng, Thao T Doan, Karim R Masri
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/11/3/e005742.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://rmdopen.bmj.com/content/11/3/e005742.full

Similar Items